Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry P Erba

Showing results (31-40 of 123) with videos related to

Pageof 13
Sort By:
Cancer|October 21, 2010
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemiaMikkael A Sekeres, Jaroslaw P Maciejewski, Harry P Erba, et al.
Investigational New Drugs|February 12, 2013
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)Harry P Erba, Hamid Sayar, Mark Juckett, et al.
Plos One|February 16, 2017
Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaKentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, et al.
Blood|October 5, 2013
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemiaSucha Nand, Megan Othus, John E Godwin, et al.
Plos One|December 2, 2016
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaKentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, et al.
Blood|April 6, 2018
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studiesAbby Statler, Megan Othus, Harry P Erba, et al.
Leukemia Research|February 7, 2018
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)Anjali S Advani, Hongli Li, Laura C Michaelis, et al.
Haematologica|July 11, 2015
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOGRoland B Walter, Megan Othus, Bob Löwenberg, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2015
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation studyJohn F DiPersio, Harry P Erba, Richard A Larson, et al.
Cancer|February 22, 2017
Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trialsXiaoyu Qu, Megan Othus, Jerry Davison, et al.
Pageof 13

Showing results (31-40 of 123) with videos related to

Sort By:
Pageof 13
Cancer|October 21, 2010
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemiaMikkael A Sekeres, Jaroslaw P Maciejewski, Harry P Erba, et al.
Investigational New Drugs|February 12, 2013
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)Harry P Erba, Hamid Sayar, Mark Juckett, et al.
Plos One|February 16, 2017
Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaKentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, et al.
Blood|October 5, 2013
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemiaSucha Nand, Megan Othus, John E Godwin, et al.
Plos One|December 2, 2016
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaKentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, et al.
Blood|April 6, 2018
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studiesAbby Statler, Megan Othus, Harry P Erba, et al.
Leukemia Research|February 7, 2018
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)Anjali S Advani, Hongli Li, Laura C Michaelis, et al.
Haematologica|July 11, 2015
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOGRoland B Walter, Megan Othus, Bob Löwenberg, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2015
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation studyJohn F DiPersio, Harry P Erba, Richard A Larson, et al.
Cancer|February 22, 2017
Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trialsXiaoyu Qu, Megan Othus, Jerry Davison, et al.
Pageof 13